Global Hospital Infection Therapeutics (Hospital-Acquired Pneumonia, Urinary Tract, Gastrointestinal, Bloodstream, Surgical Site Infections and Other Hospital Infections) Market - Forecast to 2020

Hospital infection is also referred to as healthcare-associated infection (HCAI) or nosocomial infection or hospital-acquired infection (HAI). HAI are those infections that develop in patients undergoing treatment in a healthcare setting, it also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. According to the Centers for Disease Control and Prevention (CDC), in 2011, approximately 1.7 million HAIs from all types of bacteria combined are reported each year in the U.S. In addition, according to the ECDC estimates, in 2013 around 4.1 million patients were diagnosed with HAI in Europe (including 30 nations).

Global hospital infection therapeutics market has been classified into three major segments, based on the type of drugs, namely, antibacterial, antiviral and antifungal drugs. In 2013, the antibacterial drugs segment held the largest share (70.7%) in the global hospital infection therapeutics market. Antibacterial drugs segment is also expected to be the fastest growing segment in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. The global hospital infection therapeutics market has been also classified into six major segments, based on the type of major hospital infections, namely, hospital-acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. In 2013, the hospital-acquired pneumonia segment held the largest share (over 20%) in the global hospital infection therapeutics market. Urinary tract infections segment is expected to be the fastest growing segment during the forecast period 2014 to 2020.

Some of the major driving factors for the growth of this market are increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. Demand for hospital infection therapeutics will especially rise in low to medium income countries due to the presence of high patient population suffering from different hospital infections, hot and humid environmental conditions, lack of standard healthcare facilities and low social awareness. However, rising multi-drug resistant bacterial strains have rendered available drugs obsolete. Moreover, increasing infection control and surveillance programs may present a threat to the growth of this market. Huge scope for the development of hospital infection therapeutics in treating range of multi-drug resistant microbes and increased penetration in emerging economies would contribute to the growth of the market in near future.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Hospital Infection Therapeutics Market Overview

Chapter 4 Hospital Infection Therapeutics Market, by Drug Type

Chapter 5 Hospital Infection Therapeutics Market, by Major Infections

Chapter 6 Hospital infection therapeutics Market, by Geography

Chapter 7 Recommendations

Chapter 8 Company Profiles

Companies Mentioned:

For more information visit http://www.researchandmarkets.com/research/wts7xd/hospital

Media Contact: Laura Wood, +353-1-481-1716, [email protected]